Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

BACKGROUND: BRAF V600 mutations occur in various nonmelanoma cancers. We undertook a histology-independent phase 2 “basket” study of vemurafenib in BRAF V600 mutation–positive nonmelanoma cancers. METHODS: We enrolled patients in six prespecified cancer cohorts; patients with all other tumor types w...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:N Engl J Med
Asıl Yazarlar: Hyman, David M., Puzanov, Igor, Subbiah, Vivek, Faris, Jason E., Chau, Ian, Blay, Jean-Yves, Wolf, Jürgen, Raje, Noopur S., Diamond, Eli L., Hollebecque, Antoine, Gervais, Radj, Elez-Fernandez, Maria Elena, Italiano, Antoine, Hofheinz, Ralf-Dieter, Hidalgo, Manuel, Chan, Emily, Schuler, Martin, Lasserre, Susan Frances, Makrutzki, Martina, Sirzen, Florin, Veronese, Maria Luisa, Tabernero, Josep, Baselga, José
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2015
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4971773/
https://ncbi.nlm.nih.gov/pubmed/26287849
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1502309
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller